

NEWS RELEASE

NEWLY-LISTED CORDLIFE AWARDED “MOST TRANSPARENT COMPANY AWARD” AT SIAS’ 13TH INVESTORS’ CHOICE AWARDS

- *Selected as runner-up for prestigious award in the New Issues Category*

Singapore, October 3, 2012 – Newly-listed Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), a cord blood and tissue banking service provider, was one of the companies at this evening’s SIAS Investors’ Choice Awards that was presented the “Most Transparent Company Award”. The Company was a runner-up in the New Issues Category, having been newly-listed on the Mainboard of the Singapore Exchange (“SGX-ST”) on March 29, 2012.

The Investors’ Choice Awards, now in its 13th year, honour companies and individuals who have achieved excellence in advancing corporate governance practices, including promoting greater corporate transparency.

Mr. Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said, “It is indeed a great honour and privilege to be selected for this prestigious award, and to be recognised for our efforts at adhering to and advocating for transparency, which we believe is a key pillar of good corporate governance.

“We are also pleased that the award comes just months after our listing on SGX-ST, as it demonstrates the confidence that the financial and investing community has in Cordlife, not just in terms of our ability to run the business and deliver results, but also in terms of our commitment to build trust in the marketplace and engage in open communications with all stakeholders. We certainly endeavour to continue providing accurate, unambiguous information in a timely manner and through the proper channels.

“We would like to thank SIAS and its partners for organising the awards, and allowing us to join the ranks of so many worthy recipients who have been relentless champions of transparency in corporate governance practices.”

The awards were presented at a dinner event held tonight at Raffles City Convention Centre.

The initial public offering of Cordlife Group Limited's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd..

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited is an award-winning and established cord blood banking service provider. Amongst the first private cord blood banks in Asia, the Group has established a dominant market leader position in Singapore*. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks.

The Group collects, processes, tests, cryo-preserved and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to cryo-preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways.

**According to the industry data found in Cordlife's prospectus dated March 21, 2012*

Cordlife's business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals & clinics such as Thomson Medical, Parkway East Hospital and Raffles Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a marketing collaboration agreement with China Cord Blood Corporation – a top operator in China holding majority shares in Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank. The Group also has an indirect 10% shareholding interest in the sole cord blood banking operator in Guangdong province: Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd.

Cordlife was amongst the first in Asia to be accredited by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is also one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2011 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7**.

***Awarded to Cordlife Hong Kong*

ISSUED ON BEHALF OF : Cordlife Group Limited
BY : Citigate Dewe Rogerson, i.MAGE Pte Ltd
1 Raffles Place
#26-02 One Raffles Place
SINGAPORE 048616
CONTACT : Ms Dolores Phua / Ms Chelsea Phua
DURING OFFICE HOURS : 6534-5122 (Office)
AFTER OFFICE HOURS : 9750-8237 / 9667-5837 (Handphone)
EMAIL : dolores.phua@citigatedrimage.com /
chelsea.phua@citigatedrimage.com

107/12/003/CGL

October 3, 2012